{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T05:46:53Z","timestamp":1776923213665,"version":"3.51.2"},"reference-count":72,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,11,29]]},"abstract":"<jats:p>Follicular lymphoma (FL) is a common indolent B-cell malignancy with a variable clinical course. An unfavorable event in its course is histological transformation to a high-grade lymphoma, typically diffuse large B-cell lymphoma. Recent studies show that genetic aberrations of MYC or its overexpression are associated with FL transformation (tFL). However, the precise molecular mechanisms underlying tFL are unclear. Here we performed the first profiling of expression of microRNAs (miRNAs) in paired samples of FL and tFL and identified 5 miRNAs as being differentially expressed. We focused on one of these miRNAs, namely miR-150, which was uniformly downmodulated in all examined tFLs (\u223c3.5-fold), and observed that high levels of MYC are responsible for repressing miR-150 in tFL by binding in its upstream region. This MYC-mediated repression of miR-150 in B cells is not dependent on LIN28A\/B proteins, which influence the maturation of miR-150 precursor (pri-miR-150) in myeloid cells. We also demonstrated that low miR-150 levels in tFL lead to upregulation of its target, namely FOXP1 protein, which is a known positive regulator of cell survival, as well as B-cell receptor and NF-\u03baB signaling in malignant B cells. We revealed that low levels of miR-150 and high levels of its target, FOXP1, are associated with shorter overall survival in FL and suggest that miR-150 could serve as a good biomarker measurable in formalin-fixed paraffin-embedded tissue. Overall, our study demonstrates the role of the MYC\/miR-150\/FOXP1 axis in malignant B cells as a determinant of FL aggressiveness and its high-grade transformation.<\/jats:p>","DOI":"10.1182\/blood-2018-06-855502","type":"journal-article","created":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T21:24:33Z","timestamp":1536873873000},"page":"2389-2400","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":48,"title":["miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels"],"prefix":"10.1182","volume":"132","author":[{"given":"Katerina","family":"Musilova","sequence":"first","affiliation":[{"name":"Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic;"},{"name":"Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Devan","sequence":"first","affiliation":[{"name":"Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katerina","family":"Cerna","sequence":"first","affiliation":[{"name":"Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic;"},{"name":"Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaclav","family":"Seda","sequence":"first","affiliation":[{"name":"Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic;"},{"name":"Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Pavlasova","sequence":"first","affiliation":[{"name":"Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic;"},{"name":"Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonali","family":"Sharma","sequence":"first","affiliation":[{"name":"Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Oppelt","sequence":"first","affiliation":[{"name":"Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Pytlik","sequence":"first","affiliation":[{"name":"First Department of Medicine \u2013 Department of Hematology, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vit","family":"Prochazka","sequence":"first","affiliation":[{"name":"Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Czech Republic;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuzana","family":"Prouzova","sequence":"first","affiliation":[{"name":"Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Czech Republic;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Trbusek","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lenka","family":"Zlamalikova","sequence":"first","affiliation":[{"name":"Department of Pathology, University Hospital Brno, Brno, Czech Republic;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kvetoslava","family":"Liskova","sequence":"first","affiliation":[{"name":"Department of Pathology, University Hospital Brno, Brno, Czech Republic;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lenka","family":"Kruzova","sequence":"first","affiliation":[{"name":"Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Czech Republic;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Jarosova","sequence":"first","affiliation":[{"name":"Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Czech Republic;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Mareckova","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Kornauth","sequence":"first","affiliation":[{"name":"Department of Clinical Pathology, Medical University Vienna, Vienna, Austria;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Simonitsch-Klupp","sequence":"first","affiliation":[{"name":"Department of Clinical Pathology, Medical University Vienna, Vienna, Austria;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana-Iris","family":"Schiefer","sequence":"first","affiliation":[{"name":"Department of Clinical Pathology, Medical University Vienna, Vienna, Austria;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olaf","family":"Merkel","sequence":"first","affiliation":[{"name":"Department of Clinical Pathology, Medical University Vienna, Vienna, Austria;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Mocikova","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Hematology, University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Burda","sequence":"first","affiliation":[{"name":"Institute of Hematology and Blood Transfusion, Prague, Czech Republic;"},{"name":"Institute of Pathological Physiology, First Medical Faculty, Charles University, Prague, Czech Republic; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katerina","family":"Machova Polakova","sequence":"first","affiliation":[{"name":"Institute of Hematology and Blood Transfusion, Prague, Czech Republic;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leos","family":"Kren","sequence":"first","affiliation":[{"name":"Department of Pathology, University Hospital Brno, Brno, Czech Republic;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiri","family":"Mayer","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clive S.","family":"Zent","sequence":"first","affiliation":[{"name":"Departments of Pathology and Laboratory Medicine and Medicine, University of Rochester Medical Center, School of Medicine and Dentistry, Rochester, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Trneny","sequence":"first","affiliation":[{"name":"First Department of Medicine \u2013 Department of Hematology, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew G.","family":"Evans","sequence":"first","affiliation":[{"name":"Departments of Pathology and Laboratory Medicine and Medicine, University of Rochester Medical Center, School of Medicine and Dentistry, Rochester, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Janikova","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Mraz","sequence":"first","affiliation":[{"name":"Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic;"},{"name":"Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"14","key":"2020071008403809000_B1","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1200\/JCO.2010.32.7577","article-title":"Transformation of indolent B-cell lymphomas","volume":"29","author":"Montoto","year":"2011","journal-title":"J Clin Oncol"},{"issue":"32","key":"2020071008403809000_B2","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2008.16.0283","article-title":"Population-based analysis of incidence and outcome of transformed non-Hodgkin\u2019s lymphoma","volume":"26","author":"Al-Tourah","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"2020071008403809000_B3","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/annonc\/mdl162","article-title":"The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma","volume":"17","author":"Gin\u00e9","year":"2006","journal-title":"Ann Oncol"},{"issue":"4","key":"2020071008403809000_B4","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00277-017-3218-0","article-title":"The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database","volume":"97","author":"Janikova","year":"2018","journal-title":"Ann Hematol"},{"issue":"17","key":"2020071008403809000_B5","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1200\/JCO.2006.09.3260","article-title":"Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma","volume":"25","author":"Montoto","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"2020071008403809000_B6","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ng.2856","article-title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma","volume":"46","author":"Okosun","year":"2014","journal-title":"Nat Genet"},{"issue":"1","key":"2020071008403809000_B7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","article-title":"Genetics of follicular lymphoma transformation","volume":"6","author":"Pasqualucci","year":"2014","journal-title":"Cell Reports"},{"issue":"8","key":"2020071008403809000_B8","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1182\/blood.V82.8.2289.2289","article-title":"p53 mutations are associated with histologic transformation of follicular lymphoma","volume":"82","author":"Lo Coco","year":"1993","journal-title":"Blood"},{"issue":"3","key":"2020071008403809000_B9","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood.V80.3.758.758","article-title":"MYC rearrangements in histologically progressed follicular lymphomas","volume":"80","author":"Yano","year":"1992","journal-title":"Blood"},{"issue":"13","key":"2020071008403809000_B10","doi-asserted-by":"crossref","first-page":"8886","DOI":"10.1073\/pnas.132253599","article-title":"Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes","volume":"99","author":"Lossos","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"2020071008403809000_B11","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/1078-0432.CCR-13-2175","article-title":"Inactivation of the CDKN2A tumor-suppressor gene by deletion or methylation is common at diagnosis in follicular lymphoma and associated with poor clinical outcome","volume":"20","author":"Alhejaily","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2020071008403809000_B12","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1182\/blood-2017-03-691345","article-title":"Can histologic transformation of follicular lymphoma be predicted and prevented?","volume":"130","author":"Kridel","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2020071008403809000_B13","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1038\/sj.leu.2404696","article-title":"Genome-wide detection of recurring sites of uniparental disomy in follicular and transformed follicular lymphoma","volume":"21","author":"Fitzgibbon","year":"2007","journal-title":"Leukemia"},{"issue":"12","key":"2020071008403809000_B14","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1182\/blood.V91.12.4677","article-title":"Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma","volume":"91","author":"Elenitoba-Johnson","year":"1998","journal-title":"Blood"},{"issue":"11","key":"2020071008403809000_B15","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1182\/blood-2013-05-500595","article-title":"Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma","volume":"123","author":"Bouska","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2020071008403809000_B16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/leu.2016.175","article-title":"Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma","volume":"31","author":"Bouska","year":"2017","journal-title":"Leukemia"},{"issue":"2","key":"2020071008403809000_B17","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2141.2006.06439.x","article-title":"Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms","volume":"136","author":"Davies","year":"2007","journal-title":"Br J Haematol"},{"issue":"2","key":"2020071008403809000_B18","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1182\/blood-2009-07-235598","article-title":"The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation","volume":"115","author":"Farinha","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2020071008403809000_B19","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.3324\/haematol.2009.021766","article-title":"Vascularization predicts overall survival and risk of transformation in follicular lymphoma","volume":"95","author":"Farinha","year":"2010","journal-title":"Haematologica"},{"issue":"6","key":"2020071008403809000_B20","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3892\/etm.2010.146","article-title":"High ratio of interfollicular CD8\/FOXP3-positive regulatory T cells is associated with a high FLIPI index and poor overall survival in follicular lymphoma","volume":"1","author":"Saifi","year":"2010","journal-title":"Exp Ther Med"},{"issue":"11","key":"2020071008403809000_B21","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1158\/1078-0432.CCR-13-2367","article-title":"Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma","volume":"20","author":"Smeltzer","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2020071008403809000_B22","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1182\/blood-2013-09-527234","article-title":"miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1","volume":"124","author":"Mraz","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2020071008403809000_B23","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1182\/blood-2011-11-394874","article-title":"MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia","volume":"119","author":"Mraz","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2020071008403809000_B24","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/leu.2014.351","article-title":"MicroRNAs in B-cell lymphomas: how a complex biology gets more complex","volume":"29","author":"Musilova","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"2020071008403809000_B25","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.cell.2007.07.021","article-title":"MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb [published correction appears in Cell. 2016;165(4):1027]","volume":"131","author":"Xiao","year":"2007","journal-title":"Cell"},{"issue":"7043","key":"2020071008403809000_B26","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nature03552","article-title":"A microRNA polycistron as a potential human oncogene","volume":"435","author":"He","year":"2005","journal-title":"Nature"},{"issue":"18","key":"2020071008403809000_B27","doi-asserted-by":"crossref","first-page":"7024","DOI":"10.1073\/pnas.0602266103","article-title":"Pre-B cell proliferation and lymphoblastic leukemia\/high-grade lymphoma in E(mu)-miR155 transgenic mice","volume":"103","author":"Costinean","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"2020071008403809000_B28","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood-2009-05-220814","article-title":"Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice","volume":"114","author":"Costinean","year":"2009","journal-title":"Blood"},{"issue":"5","key":"2020071008403809000_B29","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1080\/10428194.2016.1228932","article-title":"The significance of FOXP1 in diffuse large B-cell lymphoma","volume":"58","author":"Gascoyne","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"23","key":"2020071008403809000_B30","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1182\/blood-2014-01-553412","article-title":"FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-\u03baB to promote survival of human B cells","volume":"124","author":"van Keimpema","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2020071008403809000_B31","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3324\/haematol.2016.156455","article-title":"The small FOXP1 isoform predominantly expressed in activated B cell-like diffuse large B-cell lymphoma and full-length FOXP1 exert similar oncogenic and transcriptional activity in human B cells","volume":"102","author":"van Keimpema","year":"2017","journal-title":"Haematologica"},{"issue":"11","key":"2020071008403809000_B32","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1182\/blood-2015-08-662635","article-title":"The hematopoietic oncoprotein FOXP1 promotes tumor cell survival in diffuse large B-cell lymphoma by repressing S1PR2 signaling","volume":"127","author":"Flori","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2020071008403809000_B33","doi-asserted-by":"crossref","first-page":"E577","DOI":"10.1073\/pnas.1524677113","article-title":"Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1","volume":"113","author":"Dekker","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"2020071008403809000_B34","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1182\/blood-2004-03-1209","article-title":"Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome","volume":"104","author":"Barrans","year":"2004","journal-title":"Blood"},{"issue":"3","key":"2020071008403809000_B35","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1158\/1078-0432.1065.11.3","article-title":"Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma","volume":"11","author":"Banham","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2020071008403809000_B36","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10735-005-6521-3","article-title":"The FOXP1 transcription factor is expressed in the majority of follicular lymphomas but is rarely expressed in classical and lymphocyte predominant Hodgkin\u2019s lymphoma","volume":"36","author":"Brown","year":"2005","journal-title":"J Mol Histol"},{"issue":"16","key":"2020071008403809000_B37","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1200\/JCO.2006.05.6150","article-title":"Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma","volume":"24","author":"Sagaert","year":"2006","journal-title":"J Clin Oncol"},{"issue":"17","key":"2020071008403809000_B38","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-09-0113","article-title":"A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy","volume":"15","author":"Choi","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2020071008403809000_B39","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1200\/JCO.2010.30.0368","article-title":"Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab","volume":"29","author":"Meyer","year":"2011","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020071008403809000_B40","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1038\/leu.2012.83","article-title":"Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study [published correction appears in Leukemia. 2014;28(4):980","volume":"26","author":"Visco","year":"2012","journal-title":"Leukemia"},{"issue":"3","key":"2020071008403809000_B41","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10120-013-0313-3","article-title":"Prognostic significance of miR-34a and its target proteins of FOXP1, p53, and BCL2 in gastric MALT lymphoma and DLBCL","volume":"17","author":"He","year":"2014","journal-title":"Gastric Cancer"},{"issue":"5","key":"2020071008403809000_B42","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1600-0609.2009.01222.x","article-title":"Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas","volume":"82","author":"Nyman","year":"2009","journal-title":"Eur J Haematol"},{"issue":"2","key":"2020071008403809000_B43","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/leu.2013.224","article-title":"Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients [published correction appears in Leukemia. 2014;28(2):470]","volume":"28","author":"Wong","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"2020071008403809000_B44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2009.09.061","article-title":"MicroRNA isolation and stability in stored RNA samples","volume":"390","author":"Mraz","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"2020071008403809000_B45","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ccr.2012.08.028","article-title":"Blockade of miR-150 maturation by MLL-fusion\/MYC\/LIN-28 is required for MLL-associated leukemia","volume":"22","author":"Jiang","year":"2012","journal-title":"Cancer Cell"},{"issue":"38","key":"2020071008403809000_B46","doi-asserted-by":"crossref","first-page":"62091","DOI":"10.18632\/oncotarget.11388","article-title":"Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells","volume":"7","author":"Zemanova","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"2020071008403809000_B47","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4049\/jimmunol.157.1.81","article-title":"Maintenance of nuclear factor-kappa B\/Rel and c-myc expression during CD40 ligand rescue of WEHI 231 early B cells from receptor-mediated apoptosis through modulation of I kappa B proteins","volume":"157","author":"Schauer","year":"1996","journal-title":"J Immunol"},{"issue":"21","key":"2020071008403809000_B48","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1182\/blood-2012-10-462846","article-title":"Downregulation of FOXP1 is required during germinal center B-cell function","volume":"121","author":"Sagardoy","year":"2013","journal-title":"Blood"},{"issue":"23","key":"2020071008403809000_B49","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020071008403809000_B50","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/ijc.22800","article-title":"MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma","volume":"121","author":"Lawrie","year":"2007","journal-title":"Int J Cancer"},{"issue":"7","key":"2020071008403809000_B51","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/j.1582-4934.2008.00628.x","article-title":"Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma","volume":"13","author":"Lawrie","year":"2009","journal-title":"J Cell Mol Med"},{"issue":"5","key":"2020071008403809000_B52","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3892\/etm.2012.502","article-title":"Clinical and prognostic significance of miR-155 and miR-146a expression levels in formalin-fixed\/paraffin-embedded tissue of patients with diffuse large B-cell lymphoma","volume":"3","author":"Zhong","year":"2012","journal-title":"Exp Ther Med"},{"issue":"4","key":"2020071008403809000_B53","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood-2014-03-559690","article-title":"MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia","volume":"124","author":"Cui","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2020071008403809000_B54","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1182\/blood-2014-04-571786","article-title":"BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma","volume":"125","author":"Correia","year":"2015","journal-title":"Blood"},{"key":"2020071008403809000_B55","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.humpath.2015.11.011","article-title":"miR-31 and miR-17-5p levels change during transformation of follicular lymphoma","volume":"50","author":"Thompson","year":"2016","journal-title":"Hum Pathol"},{"issue":"7","key":"2020071008403809000_B56","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/leu.2010.91","article-title":"Mantle cell lymphoma: transcriptional regulation by microRNAs","volume":"24","author":"Di Lisio","year":"2010","journal-title":"Leukemia"},{"issue":"16","key":"2020071008403809000_B57","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1182\/blood-2008-10-184077","article-title":"Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas","volume":"113","author":"Malumbres","year":"2009","journal-title":"Blood"},{"issue":"13","key":"2020071008403809000_B58","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1182\/blood-2009-09-243147","article-title":"microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma","volume":"115","author":"Zhao","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2020071008403809000_B59","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/ng.2007.30","article-title":"Widespread microRNA repression by Myc contributes to tumorigenesis","volume":"40","author":"Chang","year":"2008","journal-title":"Nat Genet"},{"issue":"7043","key":"2020071008403809000_B60","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nature03677","article-title":"c-Myc-regulated microRNAs modulate E2F1 expression","volume":"435","author":"O\u2019Donnell","year":"2005","journal-title":"Nature"},{"issue":"18","key":"2020071008403809000_B61","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1182\/blood-2015-06-649905","article-title":"Cell of origin of transformed follicular lymphoma","volume":"126","author":"Kridel","year":"2015","journal-title":"Blood"},{"issue":"8","key":"2020071008403809000_B62","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/ni1358","article-title":"Foxp1 is an essential transcriptional regulator of B cell development","volume":"7","author":"Hu","year":"2006","journal-title":"Nat Immunol"},{"issue":"3","key":"2020071008403809000_B63","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/leu.2015.299","article-title":"FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas","volume":"30","author":"Brown","year":"2016","journal-title":"Leukemia"},{"issue":"18","key":"2020071008403809000_B64","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood-2015-02-626176","article-title":"The forkhead transcription factor FOXP1 represses human plasma cell differentiation","volume":"126","author":"van Keimpema","year":"2015","journal-title":"Blood"},{"issue":"362","key":"2020071008403809000_B65","doi-asserted-by":"crossref","first-page":"ra12","DOI":"10.1126\/scisignal.2005654","article-title":"FOXP1 potentiates Wnt\/\u03b2-catenin signaling in diffuse large B cell lymphoma","volume":"8","author":"Walker","year":"2015","journal-title":"Sci Signal"},{"issue":"23","key":"2020071008403809000_B66","doi-asserted-by":"crossref","first-page":"6227","DOI":"10.1182\/blood-2010-10-312231","article-title":"Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1","volume":"117","author":"Craig","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2020071008403809000_B67","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/blood-2017-08-799080","article-title":"FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy","volume":"131","author":"Mottok","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2020071008403809000_B68","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.immuni.2010.06.013","article-title":"MicroRNA-34a perturbs B lymphocyte development by repressing the forkhead box transcription factor Foxp1","volume":"33","author":"Rao","year":"2010","journal-title":"Immunity"},{"issue":"12","key":"2020071008403809000_B69","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1158\/1078-0432.CCR-11-0224","article-title":"MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP","volume":"17","author":"Alencar","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2020071008403809000_B70","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/cam4.29","article-title":"MicroRNA-142 is mutated in about 20% of diffuse large B-cell lymphoma","volume":"1","author":"Kwanhian","year":"2012","journal-title":"Cancer Med"},{"key":"2020071008403809000_B71","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2119\/molmed.2014.00214","article-title":"Opposite prognostic significance of cellular and serum circulating microRNA-150 in patients with chronic lymphocytic leukemia","volume":"21","author":"Stamatopoulos","year":"2015","journal-title":"Mol Med"},{"issue":"3","key":"2020071008403809000_B72","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/1940-6207.CAPR-11-0370","article-title":"Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies","volume":"5","author":"Pritchard","year":"2012","journal-title":"Cancer Prev Res (Phila)"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/132\/22\/2389\/1746044\/blood855502.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/132\/22\/2389\/1746044\/blood855502.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T03:15:02Z","timestamp":1693883702000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/132\/22\/2389\/107707\/miR150-downregulation-contributes-to-the-highgrade"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,29]]},"references-count":72,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2018,11,29]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2018-06-855502","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,29]]}}}